TrialA Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects
Trial details
- Registry ID
- NCT04880642
- Phase
- Phase 3
Drug research
C21
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as Buloxibutid, Compound 21
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Trial to Investigate Recovery From COVID-19 With C21 in Adult SubjectsNCT04880642 | Vicore Pharma AB | Phase 3 | Completed | 2022-04-25Actual |
| Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPFNCT04533022 | Vicore Pharma AB | Phase 2 | Completed | 2024-03-30Actual |
Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF
Trial details
- Registry ID
- NCT04533022
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |